Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings

    loading  Checking for direct PDF access through Ovid

Excerpt

In today's “Era of Biologics,” traditional biological agents such as infliximab and adalimumab and newer agents such as vedolizumab and ustekinumab represent the most effective and expensive class of pharmacotherapy options for the treatment of inflammatory bowel diseases (IBDs), namely Crohn disease and ulcerative colitis. More recent studies show that pharmacy utilization costs, driven mainly by biologics use, are primary drivers of IBD economics, outpacing acute care costs, including hospitalizations (1,2). Consequently, the anticipated advent of biosimilars represents the potential to generate cost savings and increase patient access to necessary treatment.

Related Topics

    loading  Loading Related Articles